featured
Combination Therapy With Pioglitazone/Exenatide Metformin and Hepatic Fibrosis and Steatosis Prevalence
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Diabetes, Obesity & Metabolism
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Combination Therapy with Pioglitazone/Exenatide Metformin Reduces the Prevalence of Hepatic Fibrosis and Steatosis: The Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT) Trial
Diabetes Obes Metab 2022 Jan 10;[EPub Ahead of Print], O Lavynenko, M Abdul-Ghani, M Alatrach, C Puckett, J Adams, S Abdelgani, N Alkhouri, C Triplitt, GD Clarke, JA Vasquez, J Li, E Cersosimo, A Gastaldelli, RA DeFronzoFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.